A NOVEL RECEPTOR: 14-3-3 AXIS REGULATES CELL FUNCTION
Project Number5R01AI050744-04
Contact PI/Project LeaderLOPEZ, ANGEL F
Awardee OrganizationINSTITUTE OF MEDICAL AND VET SCIENCE
Description
Abstract Text
DESCRIPTION (provided by applicant): The overall aim of this application is the molecular and functional characterization of a novel receptor-initiated signaling pathway we have identified in hematopoietic cells. Activation of this pathway is triggered by engagement of the GM-CSF/IL-3/IL-5 receptors in myeloid cells and of the GPIb-IX-V receptor complex in platelets. A unique feature of this pathway is its initiation by receptor site-specific serine phosphorylation and recruitment of phosphoserine-binding adaptor protein 14-3-3. The specific aims of this proposal are to:
1. Biochemically characterize the interactions between receptors, 14-3-3 and PI 3-kinase seeking to determine the assemblage and architecture of these complexes.
2. Determine the functional significance of these complexes in myeloid cells and platelets in vitro.
3. Determine the functional significance of this pathway in vivo using specific animal models.
This proposal has the long-term aim of understanding the mechanism of activation of myeloid cells and platelets, two hematopoietic cell types essential for a living organism. In the case of myeloid cells, these studies have the potential to unravel the poorly understood survival and "primary" effects of GM-CSF, IL-3 and IL-5, which the body utilizes to combat invading pathogens. In platelets, these studies should provide essential knowledge on the activation of the receptor GPIb-IX-V complex and its role in maintaining homeostasis. Importantly, activation of the novel signaling pathway we have uncovered is likely to be involved in debilitating human pathologies and its characterization may provide novel targets for interfering with its assemblage for therapeutic purposes. In myeloid cells, abnormal activation of the GM-CSF, IL-3 and IL-5 receptors has been implicated in myeloid leukaemias and chronic inflammatory diseases such as asthma and rheumatoid arthritis. In platelets, abnormal activation of the GPIb-LX-V complex is involved in thrombosis that triggers unstable angina, myocardial infarction and stroke, the leading combined causes of death in the western world.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
740198254
UEI
Project Start Date
15-September-2002
Project End Date
30-June-2007
Budget Start Date
01-July-2005
Budget End Date
30-June-2006
Project Funding Information for 2005
Total Funding
$225,000
Direct Costs
$225,000
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$225,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI050744-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI050744-04
Patents
No Patents information available for 5R01AI050744-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI050744-04
Clinical Studies
No Clinical Studies information available for 5R01AI050744-04
News and More
Related News Releases
No news release information available for 5R01AI050744-04
History
No Historical information available for 5R01AI050744-04
Similar Projects
No Similar Projects information available for 5R01AI050744-04